Clinical Applications of MicroRNAs in Acute Myeloid Leukemia: A Mini-Review.

AML acute myeloid leukemia miR microRNA review

Journal

Frontiers in oncology

ISSN: 2234-943X

Titre abrégé: Front Oncol

Pays: Switzerland

ID NLM: 101568867

Informations de publication

Date de publication:
2021

Historique:

received: 10 03 2021

accepted: 13 07 2021

entrez: 30 8 2021

pubmed: 31 8 2021

medline: 31 8 2021

Statut: epublish

Résumé

MicroRNAs (miRs) are short non-coding RNAs, typically 18-25 nucleotides in length, that are critically important, through their direct effects on target mRNAs, in a variety of cellular processes including cell differentiation, proliferation and survival. Dysregulated miR expression has been identified in numerous cancer types including acute myeloid leukemia (AML). From a clinical standpoint, several miRs have been shown to associate with prognosis in AML patients. Furthermore, they also carry the potential to be used as biomarkers and to inform medical decision making. In addition, several preclinical studies have provided strong rationale to develop novel therapeutic strategies to target miRs in AML. This review will focus on potential clinical applications of miRs in adult AML and will discuss unique miR signatures in specific AML subtypes, their role in prognostication and response to therapy, as well as miRs that are promising therapeutic targets and ongoing clinical trials directed towards targeting clinically relevant miRs in AML that could allow for improvements in current treatment strategies.

Identifiants

DOI: 10.3389/fonc.2021.679022 PMID: 34458136 PMC: PMC8385666

pubmed: 34458136

doi: 10.3389/fonc.2021.679022

pmc: PMC8385666

doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

679022

Subventions

Organisme : NCI NIH HHS

ID : UM1 CA186712

Pays : United States

Informations de copyright

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cancer Res. 2016 Aug 1;76(15):4470-80

pubmed: 27280396

Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40

pubmed: 18832181

Blood. 2008 May 15;111(10):5078-85

pubmed: 18337557

Blood. 2015 Oct 22;126(17):2005-15

pubmed: 26361793

Blood. 2017 Jan 26;129(4):424-447

pubmed: 27895058

Eur J Haematol. 2008 Oct;81(4):304-10

pubmed: 18573170

Cancer Biomark. 2018;22(1):101-110

pubmed: 29630523

Blood. 2012 Jun 21;119(25):6025-31

pubmed: 22566605

Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7080-5

pubmed: 17438277

Blood. 2011 Jan 27;117(4):1121-9

pubmed: 21045193

Blood. 2013 Jun 20;121(25):4977-84

pubmed: 23550041

J Clin Oncol. 2010 Feb 1;28(4):596-604

pubmed: 20026798

Blood. 2008 Mar 15;111(6):3183-9

pubmed: 18187662

BMC Cancer. 2019 Jan 30;19(1):109

pubmed: 30700251

Bone Marrow Transplant. 2018 Sep;53(9):1089-1095

pubmed: 29515250

Oncotarget. 2017 Jan 10;8(2):3666-3682

pubmed: 27705921

Hepatology. 2018 Apr;67(4):1392-1407

pubmed: 29108133

J Hematol Oncol. 2013 Mar 16;6:21

pubmed: 23497456

Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8

pubmed: 20368434

Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11511-6

pubmed: 23798388

Blood. 2014 Aug 28;124(9):1502-12

pubmed: 25006123

Nat Rev Genet. 2012 Apr 18;13(5):358-69

pubmed: 22510765

Oncotarget. 2016 Nov 22;7(47):78095-78109

pubmed: 27801668

Hematology. 2014 Jan;19(1):18-21

pubmed: 23602072

Leukemia. 2013 Apr;27(4):871-8

pubmed: 23178755

J Clin Oncol. 2010 May 20;28(15):2529-37

pubmed: 20406941

PLoS One. 2008 May 14;3(5):e2141

pubmed: 18478077

Leuk Lymphoma. 2017 Sep;58(9):1-15

pubmed: 28084850

Clin Cancer Res. 2013 Apr 15;19(8):2187-96

pubmed: 23444217

J Clin Oncol. 2013 Jun 10;31(17):2086-93

pubmed: 23650424

Leukemia. 2017 Apr;31(4):808-820

pubmed: 27740637

Clin Cancer Res. 2013 May 1;19(9):2355-67

pubmed: 23493348

Leukemia. 2015 Oct;29(10):1981-92

pubmed: 25971362

Science. 2004 Jan 2;303(5654):83-6

pubmed: 14657504

Cancer Cell. 2016 Feb 8;29(2):214-28

pubmed: 26832662

Clin Cancer Res. 2017 Jun 15;23(12):3025-3034

pubmed: 27881579

Blood. 2002 Dec 15;100(13):4325-36

pubmed: 12393746

Leukemia. 2014 May;28(5):1022-32

pubmed: 24270738

Blood. 2010 Nov 4;116(18):3622-6

pubmed: 20656931

Oncol Lett. 2019 Jun;17(6):5793-5802

pubmed: 31186806

PLoS One. 2013 Sep 24;8(9):e75815

pubmed: 24086639

Clin Cancer Res. 2021 Feb 15;27(4):1139-1149

pubmed: 33208342

Cell. 2009 Jan 23;136(2):215-33

pubmed: 19167326

Blood. 2016 May 19;127(20):2391-405

pubmed: 27069254

PLoS One. 2019 Mar 20;14(3):e0213078

pubmed: 30893351

PLoS Biol. 2005 Mar;3(3):e85

pubmed: 15723116

Nature. 2004 Sep 16;431(7006):350-5

pubmed: 15372042

Oncotarget. 2016 May 24;7(21):30250-7

pubmed: 26862847

J Clin Oncol. 2010 Dec 20;28(36):5257-64

pubmed: 21079133

N Engl J Med. 2013 May 2;368(18):1685-94

pubmed: 23534542

Leuk Lymphoma. 2020 Jun;61(6):1484-1492

pubmed: 32037935

Cancer Res. 2014 Apr 1;74(7):2094-105

pubmed: 24477595

N Engl J Med. 2008 May 1;358(18):1919-28

pubmed: 18450603

Cell. 2004 Jan 23;116(2):281-97

pubmed: 14744438

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3945-50

pubmed: 18308931

Leukemia. 2015 Nov;29(11):2143-53

pubmed: 26055302

Blood. 2017 Sep 14;130(11):1290-1301

pubmed: 28751524

Curr Opin Hematol. 2008 Jul;15(4):352-8

pubmed: 18536574

Hematology Am Soc Hematol Educ Program. 2010;2010:47-55

pubmed: 21239770